Regular ArticleA Phase II Study of Topotecan in Patients with Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study☆
References (12)
NIH
(1996)- et al.
Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
J Clin Oncol
(1985) - et al.
Camptothecin and its analogs: an overview of their potential in cancer therapeutics
Ann NY Acad Sci
(1996) Topotecan in small cell lung cancer
Semin Oncol
(1997)- et al.
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor
J Clin Oncol
(1992)
Cited by (100)
Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement
2023, Gynecologic OncologyImmunotherapy in oncogynaecology
2023, Bulletin du CancerSystemic therapy for advanced cervical cancer: Leveraging the historical threshold of overall survival
2023, Critical Reviews in Oncology/HematologySystemic therapy in cervical cancer: 30 years in review
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :The introduction of chemoradiation with cisplatin as the primary treatment of patients with locally advanced cervical cancer as well as the modest survival of the patients with recurrent or metastatic disease despite palliative chemotherapy prompted the investigation of non-platinum compounds activity in cervical cancer. Among several drugs tested in phase II trials paclitaxel (McGuire et al., 1996; Kudelka et al., 1996) – especially in cervical non-squamous carcinomas (Curtin et al., 2001) – camptothecin derivatives irinotecan (Verschraegen et al., 1997; Lhommé et al., 1999; Look et al., 1998a) and topotecan (in 5-days dosage schedules) (Muderspach et al., 2001; Bookman et al., 2000), vinorelbine (Morris et al., 1998) and ifosfamide (Carvellino et al., 1990) showed modest activity in this group of patients treated with cisplatin. The above results also prompted to combine these agents with cisplatin attempting to combinations of paclitaxel and cisplatin (Moore et al., 2004), ifosfamide with mesna and cisplatin (Omura et al., 1997) and topotecan – used in a 3-day regimen at 0,75 mg/m2 to reduce myelotoxicity – with cisplatin (Long et al., 2005) were compared with the established cisplatin monotherapy.
Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells
2017, Free Radical Biology and Medicine
- ☆
This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).
The following Gynecologic Oncology Group institutions participated in this study: University of Southern California Medical Center at Los Angeles, University of Mississippi Medical Center, Indiana University Medical Center, Bowman Gray School of Medicine of Wake Forest University, The Albany Medical College of Union University, University of California Medical Center at Irvine, Eastern Virginia Medical School, The Johns Hopkins Oncology Center, University of Texas M.D. Anderson Cancer Center, and University of Toronto/Sunnybrook Regional Cancer Center.
- 2
To whom correspondence should be addressed at Division of Gynecologic Oncology, 1441 Eastlake Avenue No. 7417, Los Angeles, CA 90033. Fax: (323) 226-2734. E-mail: [email protected]. Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.